or Try an Advanced Search...

    Anthrax Vaccines Stocks List

    Symbol Grade Name % Change
    ALT D Altimmune, Inc. 1.53
    EBS C Emergent Biosolutions, Inc. 17.88
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Anthrax Biodefense Biological Warfare Chemical Warfare Medicine Vaccines Athene Blood Plasma Chemical Warfare Agents Choline Cholinesterase Chronic Lymphocytic Leukemia Decontamination Drugs FDA Graft Versus Host Disease Host Disease Inflammatory Bowel Disease Influenza Lotion

    Related ETFs - A few ETFs which own one or more of the above listed Anthrax Vaccines stocks.

    Symbol Grade Name Weight
    GERM C ETFMG Treatments Testing and Advancements ETF 1.27
    LABD D Direxion Daily S&P Biotech Bear 3X Shares 0.96
    XBI D SPDR S&P Biotech ETF 0.75
    LABU D Direxion Daily S&P Biotech Bull 3X Shares 0.45
    SDD D ProShares UltraShort SmallCap600 0.31
    View all Anthrax Vaccines ETFs...
    Compare ETFs
    Compare GERM to LABU Compare GERM to XBI Compare XBI to SDD

        Anthrax Vaccines Stocks Recent News

        Date Stock Title
        May 2 EBS Q1 2024 Emergent BioSolutions Inc Earnings Call
        May 2 EBS Emergent BioSolutions Inc. (NYSE:EBS) Q1 2024 Earnings Call Transcript
        May 2 ALT Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
        May 2 EBS Why Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
        May 2 EBS Emergent BioSolutions gains as results top estimates, co to cut 300 jobs
        May 2 EBS Emergent BioSolutions Inc (EBS) (Q1 2024) Earnings Call Transcript Highlights: A Strong Start ...
        May 2 EBS PRESS DIGEST- Wall Street Journal - May 2
        May 2 EBS Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript
        May 2 EBS Emergent BioSolutions Inc. (EBS) Q1 2024 Earnings Call Transcript
        May 2 EBS Emergent BioSolutions Inc. 2024 Q1 - Results - Earnings Call Presentation
        May 1 EBS Emergent BioSolutions Reports Surprising Q1 2024 Earnings, Exceeding Revenue and Net Income ...
        May 1 EBS Narcan-Maker Emergent BioSolutions to Cut 300 Jobs, Close Facilities
        May 1 EBS Emergent Biosolutions Non-GAAP EPS of $0.59 beats by $1.45, revenue of $300.4M beats by $75.9M
        May 1 EBS Emergent BioSolutions Reports First Quarter 2024 Financial Results
        May 1 EBS Emergent BioSolutions to lay off about 300 employees
        May 1 EBS UPDATE 2-Emergent BioSolutions to lay off about 300 employees
        May 1 EBS Emergent BioSolutions announces reduction of about 300 employees
        May 1 EBS Emergent BioSolutions Announces Strategic Operational Changes to Stabilize Financial Position
        May 1 EBS Emergent BioSolutions Releases New Survey Findings Underscoring the Need to Continue Expanding Access & Increasing Awareness to Naloxone
        May 1 ALT Altimmune to Participate at Two Upcoming Conferences
        Related Industries: Biotechnology
        Related Stock Lists: Anthrax Biodefense Biological Warfare Chemical Warfare Medicine Vaccines Athene Blood Plasma Chemical Warfare Agents Choline Cholinesterase Chronic Lymphocytic Leukemia Decontamination Drugs FDA Graft Versus Host Disease Host Disease Inflammatory Bowel Disease Influenza Lotion
        Anthrax Vaccines

        Anthrax vaccines are vaccines used to prevent anthrax. Anthrax is a serious infectious disease caused by the bacterium Bacillus anthracis. Vaccines are available for both humans and animals. The human anthrax vaccine is a killed vaccine, meaning it contains dead bacteria. It is given as a series of three injections over a six-month period.

        Browse All Tags